Beam Therapeutics (BEAM) reported a Q4 loss Tuesday of $1.09 per diluted share, swinging from a profit of $1.73 a year earlier.
Analysts polled by FactSet expected a loss of $1.23.
License and collaboration revenue for the quarter ended Dec. 31 was $30.1 million, down from $316.2 million a year earlier.
Analysts surveyed by FactSet expected $17.2 million.
As of Dec. 31, 2024, cash, cash equivalents and marketable securities were $850.7 million, compared with $1.2 billion a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。